Clinical Network Services (CNS) and Biopharma Global have signed a cooperative partnership agreement.
This partnership aims to provide a broad and a comprehensive suite of regulatory services to meet the increased demand from international markets seeking uniquely experienced regulatory capabilities.
Together, CNS and Biopharma Global will be able to offer high-level solutions to the global biotechnology industry through combining CNS’ global product development & regulatory affairs consultancy arm, BioDesk, and Biopharma Global’s niche expertise in Orphan Drug Designations (ODDs).
Managing director of CNS, Russell Neal, said, “We are delighted to be collaboratively working with Biopharma Global and deepening our Orphan Drug expertise through their highly respected regulatory team. We consider this synergy key in providing more effective support for clients as they implement their program strategies and add greater value to their IP.”